Sanofi’s Myqorzo and Redemplo approved in China

China’s National Medical Products Administration has approved two innovative medicines licensed to French pharma major Sanofi (Euronext: SAN), Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels, in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control.

Myqorzo is licensed from US biotech Cytokinetics (Nasdaq: CYTK), which announced the Chinese authorization last month, noting that Sanofi would market the drug there.

That deal followed a move by the French pharma to establish a $1 billion manufacturing site in the country, marking Sanofi’s largest investment in China to date.